glycopyrrolate Side Effects
Also known as: Seebri, Lonhala
Analysis of 5,225 adverse event reports submitted to the FDA from 2001 to 2025.
Total Reports
5,225
Death-Related
630
12.1% of reports
Hospitalizations
2,218
42.4% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 630 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 237 |
| PNEUMONIA | 56 |
| DYSPNOEA | 50 |
| OFF LABEL USE | 49 |
| RESPIRATORY FAILURE | 47 |
| CARDIAC ARREST | 36 |
| DISEASE PROGRESSION | 35 |
| ASTHENIA | 34 |
| DIARRHOEA | 30 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 28 |
| FATIGUE | 28 |
| FALL | 27 |
| PRODUCT USE IN UNAPPROVED INDICATION | 26 |
| ACUTE KIDNEY INJURY | 22 |
| WEIGHT DECREASED | 22 |
| PAIN | 21 |
| SEPSIS | 21 |
| PRURITUS | 20 |
| VOMITING | 19 |
| ACUTE RESPIRATORY FAILURE | 18 |
Reactions in Hospitalization Reports
Top reactions in 2,218 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 524 |
| ASTHMA | 413 |
| PNEUMONIA | 397 |
| WHEEZING | 388 |
| COUGH | 267 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 252 |
| CONDITION AGGRAVATED | 200 |
| FATIGUE | 198 |
| NAUSEA | 193 |
| CHEST DISCOMFORT | 191 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 184 |
| VOMITING | 184 |
| OFF LABEL USE | 178 |
| PYREXIA | 172 |
| DRUG INEFFECTIVE | 171 |
| ASTHENIA | 153 |
| PRODUCTIVE COUGH | 148 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 147 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 145 |
| FALL | 140 |
Nearby — Related Medications
What the FAERS Data Reveals About glycopyrrolate Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 5,225 voluntary reports linked to glycopyrrolate and its brand equivalents (Seebri, Lonhala), spanning 2001 through 2025. Of those, 630 (12.1%) listed death as an outcome and 2,218 (42.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 55% were female and 44% male; age distribution skews toward 45-64, with 1,066 reports in that bracket. The single most reported reaction is dyspnoea with 1,000 submissions, followed by asthma and wheezing.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.